Neurolixis was recently showcased as the 'Biotech Of The Week" by LaBiotech.eu, the online European biotech networking website. The LaBiotech.eu article drew attention to Neurolixis' CNS drug development programs: NLX-112 for treatment of dyskinesia in Parkinson's disease, a disorder principally found in elderly patients; and NLX-101 for treatment of respiratory dysfunction in Rett syndrome, a rare orphan disorder that manifests itself in young girls.

Read the LaBiotech.eu article here.